REGENXBIO Price to Book Ratio 2014-2021 | RGNX

Historical price to book ratio values for REGENXBIO (RGNX) over the last 10 years. The current price to book ratio for REGENXBIO as of October 22, 2021 is 3.03.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

REGENXBIO Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-10-22 36.14 3.03
2021-06-30 38.85 $11.92 3.26
2021-03-31 34.11 $13.05 2.61
2020-12-31 45.36 $10.08 4.50
2020-09-30 27.52 $11.11 2.48
2020-06-30 36.83 $10.67 3.45
2020-03-31 32.38 $11.30 2.87
2019-12-31 40.97 $12.17 3.37
2019-09-30 35.60 $12.71 2.80
2019-06-30 51.37 $13.46 3.82
2019-03-31 57.31 $13.30 4.31
2018-12-31 41.95 $14.09 2.98
2018-09-30 75.50 $13.84 5.46
2018-06-30 71.75 $9.83 7.30
2018-03-31 29.85 $9.38 3.18
2017-12-31 33.25 $5.85 5.69
2017-09-30 32.95 $6.26 5.27
2017-06-30 19.75 $6.86 2.88
2017-03-31 19.30 $7.04 2.74
2016-12-31 18.55 $6.11 3.04
2016-09-30 14.01 $6.81 2.06
2016-06-30 8.00 $7.41 1.08
2016-03-31 10.80 $7.92 1.36
2015-12-31 16.60 $8.24 2.01
2015-09-30 22.03 $8.43 2.61
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.540B $0.155B
REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76